TOVX

Company Overview — What Does Theriva Biologics, Inc. Do?

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. Theriva Biologics, Inc. (TOVX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven A. Shallcross and employs approximately 20 people, headquartered in ANN ARBOR, Maryland. With a market capitalization of $10M, TOVX is one of the notable companies in the Healthcare sector.

Theriva Biologics, Inc. (TOVX) Stock Rating — Reduce (April 2026)

As of April 2026, Theriva Biologics, Inc. receives a Reduce rating with a composite score of 22.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TOVX ranks #3,556 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Theriva Biologics, Inc. ranks #565 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TOVX Stock Price and 52-Week Range

Theriva Biologics, Inc. (TOVX) currently trades at $0.23. The stock lost $0.03 (10.3%) in the most recent trading session. The 52-week high for TOVX is $1.50, which means the stock is currently trading -84.6% from its annual peak. The 52-week low is $0.16, putting the stock 41.7% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is TOVX Overvalued or Undervalued? — Valuation Analysis

Theriva Biologics, Inc. (TOVX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.74x, versus the sector average of 2.75x.

At current multiples, Theriva Biologics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Theriva Biologics, Inc. Profitability — ROE, Margins, and Quality Score

Theriva Biologics, Inc. (TOVX) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -191.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -77.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TOVX Debt, Balance Sheet, and Financial Health

Theriva Biologics, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.74x, suggesting adequate working capital coverage. Total debt on the balance sheet is $2M. Cash and equivalents stand at $8M.

TOVX has a beta of 0.78, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Theriva Biologics, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Theriva Biologics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Theriva Biologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.08. Net income for the quarter was $-29M. Operating income came in at $-30M.

In FY 2025, Theriva Biologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.08. Net income for the quarter was $-24M. Operating income came in at $-24M.

In Q3 2025, Theriva Biologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q2 2025, Theriva Biologics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.93. Net income for the quarter was $-13M. Operating income came in at $-13M.

Over the past 8 quarters, Theriva Biologics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing TOVX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TOVX Dividend Yield and Income Analysis

Theriva Biologics, Inc. (TOVX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TOVX Momentum and Technical Analysis Profile

Theriva Biologics, Inc. (TOVX) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

TOVX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Theriva Biologics, Inc. (TOVX) ranks #565 out of 838 stocks based on the Blank Capital composite score. This places TOVX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TOVX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TOVX vs S&P 500 (SPY) comparison to assess how Theriva Biologics, Inc. stacks up against the broader market across all factor dimensions.

TOVX Next Earnings Date

No upcoming earnings date has been announced for Theriva Biologics, Inc. (TOVX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TOVX? — Investment Thesis Summary

The quantitative profile for Theriva Biologics, Inc. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, Theriva Biologics, Inc. (TOVX) earns a Reduce rating with a composite score of 22.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TOVX stock.

Related Resources for TOVX Investors

Explore more research and tools: TOVX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TOVX head-to-head with peers: TOVX vs AZN, TOVX vs SLGL, TOVX vs VMD.